GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E32.62 EPS (ttm)2.64 Insider Own0.09% Shs Outstand1.25B Perf Week3.16%
Market Cap107.95B Forward P/E12.75 EPS next Y6.76 Insider Trans-1.95% Shs Float1.25B Perf Month21.80%
Income3.33B PEG18.83 EPS next Q1.49 Inst Own83.00% Short Float / Ratio1.65% / 2.55 Perf Quarter38.30%
Sales27.14B P/S3.98 EPS this Y-2.50% Inst Trans0.68% Short Interest20.73M Perf Half Y33.80%
Book/sh16.80 P/B5.13 EPS next Y-4.79% ROA5.20% Target Price81.75 Perf Year23.11%
Cash/sh4.52 P/C19.07 EPS next 5Y1.73% ROE16.20% 52W Range57.17 - 86.15 Perf YTD18.80%
Dividend2.92 P/FCF20.30 EPS past 5Y-13.10% ROI16.40% 52W High0.13% Beta0.45
Dividend %3.39% Quick Ratio1.20 Sales past 5Y-2.10% Gross Margin74.60% 52W Low50.90% ATR1.89
Employees14400 Current Ratio1.30 Sales Q/Q-5.10% Oper. Margin22.10% RSI (14)83.12 Volatility1.61% 2.58%
OptionableYes Debt/Eq1.20 EPS Q/Q-30.90% Profit Margin12.30% Rel Volume0.50 Prev Close85.42
ShortableYes LT Debt/Eq1.09 EarningsOct 27 AMC Payout109.20% Avg Volume8.13M Price86.26
Recom2.50 SMA206.08% SMA5020.33% SMA20034.15% Volume4,028,739 Change0.98%
Oct-31-22Upgrade Barclays Underweight → Equal Weight $60 → $76
Oct-28-22Upgrade Truist Hold → Buy $76 → $91
Oct-28-22Upgrade Piper Sandler Neutral → Overweight $79 → $96
Oct-28-22Reiterated Wells Fargo Equal Weight $74 → $75
Oct-28-22Reiterated RBC Capital Mkts Outperform $79 → $82
Oct-28-22Reiterated JP Morgan Overweight $80 → $87
Oct-28-22Reiterated Jefferies Buy $78 → $86
Oct-28-22Reiterated Cowen Outperform $75 → $80
Oct-28-22Reiterated BMO Capital Markets Market Perform $63 → $72
Oct-04-22Upgrade JP Morgan Neutral → Overweight $72 → $80
Show Previous Ratings
Nov-25-22 09:00AM
Nov-23-22 09:00AM
09:00AM
07:45AM
Nov-22-22 11:53AM
11:40AM Loading…
11:40AM
09:15AM
Nov-21-22 09:23AM
09:00AM
Nov-18-22 02:54PM
02:52PM
02:02PM
01:45PM
Nov-17-22 09:40AM
09:02AM
09:00AM Loading…
09:00AM
Nov-15-22 04:05PM
Nov-13-22 08:00AM
Nov-12-22 10:15AM
Nov-11-22 09:00AM
Nov-10-22 11:40AM
10:05AM
09:30AM
Nov-08-22 02:29PM
12:01PM
11:22AM
11:00AM
05:43AM
Nov-07-22 01:20PM
12:14PM
09:31AM Loading…
Nov-05-22 09:31AM
Nov-04-22 12:35PM
12:15PM
11:18AM
10:45AM
09:00AM
Nov-03-22 01:29PM
01:25PM
01:16PM
09:15AM
Nov-02-22 12:56PM
10:19AM
08:55AM
08:00AM
07:01AM
Nov-01-22 12:44PM
09:03AM
09:00AM
Oct-31-22 09:00AM
09:00AM
Oct-28-22 05:35PM
04:48PM
04:04PM
03:42PM
03:00PM
01:06PM
11:07AM
10:08AM
03:56AM
02:45AM
Oct-27-22 10:00PM
05:15PM
04:46PM
04:06PM
04:01PM
04:01PM
12:20PM
09:01AM
Oct-26-22 08:05PM
02:48PM
12:10PM
09:00AM
Oct-25-22 12:39PM
10:01AM
Oct-24-22 02:00AM
Oct-23-22 09:00AM
Oct-21-22 12:27PM
Oct-20-22 10:02AM
09:00AM
Oct-19-22 06:00PM
11:05AM
09:11AM
09:02AM
Oct-18-22 12:44PM
09:26AM
08:30AM
Oct-17-22 04:30PM
01:04PM
09:15AM
07:30AM
Oct-16-22 06:41AM
Oct-15-22 07:01AM
Oct-13-22 05:50PM
05:49PM
04:05PM
09:00AM
Oct-12-22 01:29PM
10:30AM
09:47AM
08:55AM
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilfong Diane E.SVP, Controller & CAONov 09Option Exercise63.916,416410,04734,749Nov 10 04:20 PM
Wilfong Diane E.SVP, Controller & CAONov 09Sale83.506,416535,73628,333Nov 10 04:20 PM
Wilfong Diane E.SVP, Controller & CAONov 01Option Exercise72.7016,2551,181,73844,588Nov 02 04:57 PM
Wilfong Diane E.SVP, Controller & CAONov 01Sale79.2516,2551,288,20928,333Nov 02 04:57 PM
Lofton Kevin EDirectorApr 28Option Exercise25.6216,322418,25190,525Apr 29 06:43 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 11Sale58.243,634211,64432,576Mar 14 09:46 PM
Wilfong Diane E.SVP, Controller & CAOMar 10Option Exercise0.003,297027,516Mar 14 09:30 PM
Mercier JohannaChief Commercial OfficerMar 10Option Exercise0.006,987037,765Mar 14 09:14 PM
O'Day Daniel PatrickChairman & CEOMar 10Option Exercise0.0024,0030260,396Mar 14 09:52 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 09Sale63.891,691108,03832,576Feb 11 02:57 PM
Dickinson Andrew DChief Financial OfficerFeb 06Option Exercise0.001,817060,473Feb 08 08:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise0.002,727035,303Feb 08 08:24 PM
Wilfong Diane E.SVP, Controller & CAOFeb 06Option Exercise0.001,864024,739Feb 08 08:22 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 01Sale68.5414,061963,68232,576Feb 02 06:37 PM